Bernard Jandrain

547 total citations
48 papers, 397 citations indexed

About

Bernard Jandrain is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Cell Biology. According to data from OpenAlex, Bernard Jandrain has authored 48 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Physiology and 10 papers in Cell Biology. Recurrent topics in Bernard Jandrain's work include Diabetes Treatment and Management (12 papers), Muscle metabolism and nutrition (10 papers) and Diabetes Management and Research (9 papers). Bernard Jandrain is often cited by papers focused on Diabetes Treatment and Management (12 papers), Muscle metabolism and nutrition (10 papers) and Diabetes Management and Research (9 papers). Bernard Jandrain collaborates with scholars based in Belgium and France. Bernard Jandrain's co-authors include André Scheen, M. Lacroix, F. Mosora, F Pirnay, Pierre J. Lefèbvre, G. Krzentowski, N. Pallikarakis, A Luyckx, Étienne Cavalier and Jean‐Claude Souberbielle and has published in prestigious journals such as Diabetes Care, Diabetes and Journal of Applied Physiology.

In The Last Decade

Bernard Jandrain

47 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernard Jandrain Belgium 12 154 141 140 59 50 48 397
Evan S. Berk United States 9 245 1.6× 99 0.7× 40 0.3× 17 0.3× 14 0.3× 11 393
James Gerofi Australia 9 333 2.2× 124 0.9× 36 0.3× 35 0.6× 58 1.2× 16 616
Monica L. Kearney United States 14 351 2.3× 143 1.0× 68 0.5× 13 0.2× 69 1.4× 22 583
MJ Toth United States 9 216 1.4× 103 0.7× 49 0.3× 15 0.3× 13 0.3× 10 412
Ali Al-Mamari Oman 10 149 1.0× 106 0.8× 44 0.3× 21 0.4× 14 0.3× 25 335
Nathan Pritikin United States 8 148 1.0× 93 0.7× 54 0.4× 9 0.2× 32 0.6× 14 343
D. Cuff Canada 8 322 2.1× 196 1.4× 81 0.6× 10 0.2× 17 0.3× 9 732
J. Brindisi United States 6 264 1.7× 77 0.5× 116 0.8× 8 0.1× 43 0.9× 7 390
GOROH OKANO Japan 13 187 1.2× 65 0.5× 120 0.9× 9 0.2× 39 0.8× 26 464
Amy C. Pumerantz United States 5 374 2.4× 80 0.6× 167 1.2× 8 0.1× 65 1.3× 8 508

Countries citing papers authored by Bernard Jandrain

Since Specialization
Citations

This map shows the geographic impact of Bernard Jandrain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Jandrain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Jandrain more than expected).

Fields of papers citing papers by Bernard Jandrain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Jandrain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Jandrain. The network helps show where Bernard Jandrain may publish in the future.

Co-authorship network of co-authors of Bernard Jandrain

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Jandrain. A scholar is included among the top collaborators of Bernard Jandrain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Jandrain. Bernard Jandrain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jandrain, Bernard, et al.. (2023). 766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study. Diabetes. 72(Supplement_1). 2 indexed citations
2.
Scheen, André, et al.. (2017). Protection cardio-rénale par les inhibiteurs des SGLT2 (gliflozines) : d’EMPA-REG OUTCOME à CANVAS. Revue Médicale Suisse. 13(571). 1421–1426. 3 indexed citations
3.
Scheen, André, et al.. (2017). [Complementarity between randomised controlled trials and observational registries : the example of cardiovascular prevention with SGLT2 inhibitors].. PubMed. 72(12). 563–568. 1 indexed citations
4.
Scheen, André, et al.. (2016). Protection cardiovasculaire du patient diabétique de type 2 : d’EMPA-REG OUTCOME à LEADER. Revue Médicale Suisse. 12(527). 1370–1375. 2 indexed citations
5.
Scheen, André, et al.. (2016). [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].. PubMed. 12(527). 1370–1375. 2 indexed citations
6.
Jandrain, Bernard, et al.. (2015). Forces et faiblesse des essais cliniques . Evolution en fonction de l'essor de la medecine personnalisee.. RMLG. Revue médicale de Liège. 70. 2 indexed citations
7.
Jandrain, Bernard, et al.. (2015). [STRENGTHS AND WEAKNESSES OF RANDOMISED CLINICAL TRIALS: EVOLVING CHANGES ACCORDING TO PERSONALIZED MEDICINE].. PubMed. 70(5-6). 232–6. 6 indexed citations
8.
Scheen, André, et al.. (2011). Inhibiteurs du cotransporteur du glucose SGLT rénal pour traiter le diabète de type 2. Open Repository and Bibliography (University of Liège). 2 indexed citations
9.
Scheen, André, Nicolas Paquot, Michel Letiexhe, & Bernard Jandrain. (2002). Approches pharmacologiques de prévention du diabète de type 2. Revue Médicale Suisse. -2(2402). 1480–1484. 3 indexed citations
10.
Scheen, A J, et al.. (2002). [How I explore ... the risk of a patient developing type 2 diabetes].. PubMed. 57(2). 113–5. 4 indexed citations
11.
Scheen, André, Bernard Jandrain, Nicolas Paquot, Michel Letiexhe, & Philippe Lefèbvre. (2001). Contrôle pharmacologique de l’hyperglycémie postprandiale. Open Repository and Bibliography (University of Liège). 1 indexed citations
12.
Gautier, J, F Pirnay, Bernard Jandrain, et al.. (1994). Availability of glucose ingested during muscle exercise performed under acipimox-induced lipolysis blockade. European Journal of Applied Physiology. 68(5). 406–412. 7 indexed citations
13.
14.
Jandrain, Bernard, et al.. (1992). Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension. The American Journal of Medicine. 92(4). S91–S94. 11 indexed citations
15.
16.
17.
Jandrain, Bernard, et al.. (1988). Adaptation to sports by insulin-treated diabetics. Open Repository and Bibliography (University of Liège). 1 indexed citations
18.
Scheen, André, et al.. (1988). Les cures de jeûne modifié, protidique ou glucido-protidique, dans le traitement de l'obésité morbide.. Open Repository and Bibliography (University of Liège). 2 indexed citations
19.
Gérard, Jean‐Louis, Bernard Jandrain, F Pirnay, et al.. (1986). Utilization of Oral Sucrose Load During Exercise in Humans: Effect of the α-Glucosidase Inhibitor Acarbose. Diabetes. 35(11). 1294–1301. 10 indexed citations
20.
Henrivaux, P., G. Weber, André Scheen, et al.. (1986). EFFECTS OF A STANDARDIZED VERY‐LOW‐CALORIE DIET ON THE PLASMA CONCENTRATIONS OF TRACE ELEMENTS IN OBESE SUBJECTS.. Acta Pharmacologica et Toxicologica. 59(s7). 126–129. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evan S. Berk Breakdown of academic impact, for papers by James Gerofi Breakdown of academic impact, for papers by Monica L. Kearney Breakdown of academic impact, for papers by MJ Toth Breakdown of academic impact, for papers by Ali Al-Mamari Breakdown of academic impact, for papers by Nathan Pritikin Breakdown of academic impact, for papers by D. Cuff Breakdown of academic impact, for papers by J. Brindisi Breakdown of academic impact, for papers by GOROH OKANO Breakdown of academic impact, for papers by Amy C. Pumerantz
Rankless by CCL
2026